Altimmune, Inc. (LON:0A4C)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 307.41M -5.6% |
| Revenue (ttm) | 23.37K +55.0% |
| Net Income | -69.16M |
| EPS | -0.54 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,571 |
| Open | 2.890 |
| Previous Close | 5.390 |
| Day's Range | 2.890 - 2.890 |
| 52-Week Range | 2.890 - 5.865 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About Altimmune
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland. [Read more]
Financial Performance
In 2025, Altimmune's revenue was $41,000, an increase of 105.00% compared to the previous year's $20,000. Losses were -$88.09 million, -7.33% less than in 2024.
Financial numbers in USD Financial StatementsNews
Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder
Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD; genera...
Altimmune says data from Reclaim Phase 2 trial to be presented at TLM
Altimmune (ALT) announced that a late-breaking abstract featuring results from the RECLAIM Phase 2 trial evaluating pemvidutide in adults with moderate-to-severe alcohol use disorder has been accepted...
Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
First presentation at a scientific conference of key data from RECLAIM, a multicenter Phase 2 trial of a balanced 1:1 glucagon/GLP-1 receptor agonist in alcohol use disorder (AUD)
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
MORRISTOWN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist, i...
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
Board appointments align with successful transition to late-stage clinical Company developing pemvidutide as a differentiated liver franchise with multiple potential indications As part of this transi...
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
Clinical highlights from the IMPACT Phase 2b study of pemvidutide in MASH demonstrated improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability Oral prese...
Altimmune management to meet with Truist
Analyst Devarakonda holds a meeting with management. in Boston on October 8 hosted by Truist.
Altimmune Transcript: Stifel 2026 Virtual Cardiometabolic Forum
Pemvidutide is advancing in phase III trials for MASH, leveraging its unique dual agonist mechanism and strong tolerability profile. The program targets both MASH and alcohol-related liver diseases, with robust phase II data and efficient trial execution supporting broad market potential.
Altimmune price target lowered to $17 from $18 at Evercore ISI
Evercore ISI analyst Michael DiFiore lowered the firm’s price target on Altimmune (ALT) to $17 from $18 and keeps an Outperform rating on the shares. Peak sales expectations for Alcohol…
Altimmune to Participate in Stifel Cardiometabolic Forum
GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today ann...
Altimmune Transcript: Wells Fargo 21st Annual Healthcare Conference
Management highlighted late-stage transition, active phase III enrollment for MASH, and positive phase II results in AUD and ALD. Differentiation centers on dual agonism, strong tolerability, and broad liver disease potential, with robust financials supporting execution through 2029.
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today ann...
Altimmune reports Q2 EPS (12c), consensus (12c)
“We have achieved several important milestones as we continue to successfully execute our strategy, including the initiation of the PERFORMA Phase 3 MASH trial and positive topline data from the…
Altimmune Earnings Call Transcript: Q2 2026
Strong clinical and operational progress marked Q2 2026, with phase III MASH trial initiation and robust phase II AUD results for pemvidutide. Financials remain solid with $519M cash, supporting operations through 2029, while future AUD phase III funding will rely on non-dilutive options.
Altimmune Earnings release: Q2 2026
Altimmune released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Altimmune Quarterly report: Q2 2026
Altimmune has published its Q2 2026 quarterly earnings report on August 12, 2026.
Altimmune Slides: Corporate presentation
Altimmune has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash...
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today anno...
Altimmune initiates PERFORMA trial
Altimmune (ALT) announced that the company has begun enrolling patients in the PERFORMA Phase 3 trial evaluating the efficacy and safety of pemvidutide in patients with metabolic dysfunction-associate...
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomes
Barclays says trial data highlights meaningful opportunity for Altimmune in AUD
Barclays analyst Eliana Merle notes Altimmune (ALT) reported topline data from the Phase 2 RECLAIM trial of pemvidutide for alcohol use disorder, demonstrating statistical-significance improvement acr...
H.C. Wainwright sees ‘clear Phase 2 win’ for Altimmune
H.C. Wainwright reiterates a Buy rating on Altimmune (ALT) with a $20 price target saying the company announced positive topline results from the Phase 2 RECLAIM trial evaluating pemvidutide in…
Leerink remains bullish on Altimmune following ‘positive’ AUD trial results
Leerink notes Altimmune (ALT) announced “positive topline results” from its Phase 2 RECLAIM trial of lead asset pemvidutide in patients with alcohol use disorder. Importantly, treatment with pemviduti...
Altimmune Transcript: Study result
Pemvidutide demonstrated robust efficacy in reducing heavy drinking days and achieving key FDA-recognized endpoints in moderate to severe AUD, with favorable safety and tolerability. The trial also showed potential liver benefits and significant weight loss, supporting further development in broader liver disease indications.